Medicenna Presents Preclinical Data on MDNA113 at SITC 38th Annual Meeting
Medicenna Therapeutics Corp. has shared new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), showcasing the proof of concept for their T-MASK platform technology. The company's development candidate, MDNA113, demonstrated the ability to enhance tumor-specific accumulation and increase anti-tumor activity while minimizing systemic toxicity. MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment, where it is activated by cancer-specific enzymes.
The T-MASK platform integrates tumor targeting and prolonged tumor retention with conditional activation to maximize anti-tumor efficacy and minimize systemic toxicity. Key findings from the preclinical data include reduced IL-2R agonism, no change to PD1/PDL-1 blockade, and reduced systemic lymphocyte expansion. The cleavage of MDNA113 by tumor-associated metalloproteases restores IL-2R signaling. Additionally, MDNA113 was found to be as effective as non-masked MDNA223, a bispecific antiPD1-IL-2 superkine, in tumor models.
Medicenna's T-MASK platform offers unique features, including the use of the IL-13 Superkine for tumor targeting and masking, tunable masking levels to retain good tolerability while achieving systemic activity, and prolonged tumor retention for activation of the immune-modulator. The combination of modest systemic immune simulation and potent immune activation within the tumor micro-environment holds promise for better outcomes in patients with immunosuppressive tumors.
The preclinical data presented at the SITC meeting demonstrates the potential of Medicenna's T-MASK platform and MDNA113 in advancing cancer immunotherapy. Further details can be found on Medicenna's website under the "Events and Presentations" page.
Implications of Medicenna's Preclinical Data on New Businesses in Cancer Immunotherapy
The preclinical data presented by Medicenna Therapeutics Corp. at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) could have significant implications for new businesses in the field of cancer immunotherapy. The company's T-MASK platform technology and its development candidate, MDNA113, have shown promising results in enhancing tumor-specific accumulation, increasing anti-tumor activity, and minimizing systemic toxicity.
Opportunities in Targeted Cancer Therapies
MDNA113's ability to deliver a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment, where it is activated by cancer-specific enzymes, could pave the way for more effective and targeted cancer therapies. This opens up opportunities for new businesses to explore and develop similar targeted therapies.
Maximizing Anti-Tumor Efficacy
The T-MASK platform's integration of tumor targeting, prolonged tumor retention, and conditional activation to maximize anti-tumor efficacy and minimize systemic toxicity could be a game-changer in cancer immunotherapy. This could inspire new businesses to leverage similar strategies to enhance the efficacy of their cancer treatments.
Advancing Cancer Immunotherapy
The potential of Medicenna's T-MASK platform and MDNA113 in advancing cancer immunotherapy could set a new standard in the field. New businesses can learn from Medicenna's approach and apply similar methodologies to their own research and development efforts, potentially leading to more effective and safer cancer treatments.
.svg)
